Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277472 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
A Phase 4 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00277472 is a Phase 4 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00277472, a Phase 4 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
Conditions Studied
Interventions
- DRUG HCTZ
- DRUG Valsartan/Hydrochlorothiazide
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277472
The ClinicalTrials.gov registry entry for NCT00277472 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which HCTZ is the first listed.
NCT00277472 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00277472 about?
NCT00277472 is a clinical study titled "Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension". This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
What is the current status of trial NCT00277472?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2005-11.
What conditions does trial NCT00277472 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00277472?
The interventions under investigation include: HCTZ (DRUG), Valsartan/Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00277472?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00277472 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.